Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Arcavi

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cardiovascular Drugs and Therapy|June 1, 1993
Clinical significance of genetic influences on cardiovascular drug metabolismL Arcavi, N L Benowitz
Drugs|January 1, 1995
Once-daily ofloxacin for hospitalised patients with severe bacterial infectionsZ Landau, L Arcavi, P Resnitzky
Harefuah|May 1, 1985
[Severe side-effects of captopril]L Arcavi, Z Estrov, A Caspi, et al.
Clinical Pharmacology and Therapeutics|July 1, 1994
Divergent tolerance to metabolic and cardiovascular effects of nicotine in smokers with low and high levels of cigarette consumptionL Arcavi, P Jacob, M Hellerstein, et al.
Therapeutic Drug Monitoring|October 18, 2000
Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groupsM Britzi, M Bialer, L Arcavi, et al.
Israel Journal of Medical Sciences|November 1, 1995
Acute cholecystitis caused by Campylobacter jejuniZ Landau, N L Agmon, D Argas, et al.
Experimental Hematology|August 1, 1985
In vitro functions of stromal cells from human and mouse bone marrowD Zipori, N Reichman, L Arcavi, et al.
Epilepsy Research|December 5, 1998
Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepineM Bialer, L Arcavi, S Sussan, et al.
Journal of Clinical Pharmacy and Therapeutics|March 29, 2014
Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failureR Shihmanter, I Nulman, S Goland, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cardiovascular Drugs and Therapy|June 1, 1993
Clinical significance of genetic influences on cardiovascular drug metabolismL Arcavi, N L Benowitz
Drugs|January 1, 1995
Once-daily ofloxacin for hospitalised patients with severe bacterial infectionsZ Landau, L Arcavi, P Resnitzky
Harefuah|May 1, 1985
[Severe side-effects of captopril]L Arcavi, Z Estrov, A Caspi, et al.
Clinical Pharmacology and Therapeutics|July 1, 1994
Divergent tolerance to metabolic and cardiovascular effects of nicotine in smokers with low and high levels of cigarette consumptionL Arcavi, P Jacob, M Hellerstein, et al.
Therapeutic Drug Monitoring|October 18, 2000
Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groupsM Britzi, M Bialer, L Arcavi, et al.
Israel Journal of Medical Sciences|November 1, 1995
Acute cholecystitis caused by Campylobacter jejuniZ Landau, N L Agmon, D Argas, et al.
Experimental Hematology|August 1, 1985
In vitro functions of stromal cells from human and mouse bone marrowD Zipori, N Reichman, L Arcavi, et al.
Epilepsy Research|December 5, 1998
Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepineM Bialer, L Arcavi, S Sussan, et al.
Journal of Clinical Pharmacy and Therapeutics|March 29, 2014
Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failureR Shihmanter, I Nulman, S Goland, et al.
Pageof 1